Nyheter och Pressmeddelanden från NextCell Pharma

 

NextCell’s partner PBKM exercises its TO 1 warrants

Stem cell company NextCell Pharma AB ("NXTCL") announces today that its shareholder and partner Polski Bank Komorek Macierzystych S.A. ("PBKM") is exercising all of its 320,000 warrants. This represents an investment of MSEK 1.6, corresponding to approximately 11 % of the outstanding series TO 1 warrants. The subscription period of the series TO 1 warrants

Läs mer

An additional batch of ProTrans is released prior to use in NextCell Pharma’s ongoing clinical trial.

Stem cell company NextCell Pharma AB ("NextCell") hereby announces that it has received another batch of ProTrans for clinical use. ProTrans is manufactured according to GMP (Good Manufacturing Practices) and the stem cells are selected with the company's selection algorithm to ensure quality. The selection is carried out by NextCell and the large-scale production is

Läs mer

NextCell Pharma publishes quarterly report three 2017/2018

NextCell Pharma AB (”NXTCL”, “NextCell”) today, released its third quarter report 2017/2018 (September 2017 – May 2018).

Läs mer

NextCell Pharma introduces stem cell service for adults

Stem cell company NextCell Pharma AB (“NXTCL”) announces that it is preparing to launch a service for saving adipose (fat) tissue derived stem cells during the first half of 2019. The service allows adults to save their own stem cells for future use. The stem cells are collected by liposuction, purified, processed and frozen in

Läs mer

NextCell celebrates its first-year anniversary as a listed company

The potential market for stem cell therapies is immense and development is at record speed. On July 13, 2017, stem cell company NextCell Pharma AB ("NextCell") was listed on Spotlight Stock Market (formerly AktieTorget). In his own words, CEO Mathias Svahn reflects on the company’s first year as a listed company and sends a reminder

Läs mer

Publication of scientific article regarding the clinical trial with ProTrans

The stem cell company NextCell Pharma AB ("NXTCL") today announced, that a scientific article describing the ongoing clinical trial with ProTrans has been published in Clinical Trials in Degenerative Diseases (CTDD), a peer reviewed journal encompassing clinical trials, research, therapeutics and education within the field of degenerative diseases. The scientific article was written by Per-Ola

Läs mer

NextCell applies for prediction methodology patent

The stem cell company NextCell Pharma AB ("NXTCL") has submitted another patent application. This time regarding a method for predicting if a specific patient is susceptible to treatment with the drug candidate ProTrans.

Läs mer

The Data and Safety Monitoring Board approves the usage of high-dose ProTrans in the ongoing clinical trial

Stem cell company NextCell Pharma AB ("NXTCL") announces today that the Data and Safety Monitoring Board for the clinical trial using ProTrans has given its approval for the principal investigator professor Per-Ola Carlsson and NextCell to proceed and treat 3 patients in the high-dose cohort.

Läs mer

Extended tissue establishment authorization

The stem cell company NextCell Pharma AB ("NXTCL") was inspected on 7th May 2018 by the Health and Care Inspectorate (IVO), which is the supervisor of tissue establishments. NXTCL has today received the inspection report that authorizes the business to continue without any changes being required.

Läs mer

Six patients now treated with NextCells ProTrans stem cells

NextCell Pharma AB ("NXTCL") announces that an additional three patients have been treated with ProTrans in the ongoing clinical phase I/II trial. In total 6 patients with type 1 diabetes in the low- and medium-dose-cohort have now undergone treatment.

Läs mer

Today NextCell Publishes its half-year report

NextCell Pharma AB ("NEXTCL", "NextCell") today released its half-year report (September 1, 2017 - February 28, 2018)

Läs mer

NextCell enters into Memorandum of Agreement with China General Consulting & Investment Co., Ltd.

NextCell Pharma AB ("NextCell") hereby announces that the company has entered a Memorandum of Agreement with China General Consulting & Investment Co., Ltd. (”CGCI”). The purpose of the agreement is to create a base for future co-operation. The agreement includes that the parties should prioritize working together when it comes to stem cell development and

Läs mer

The Data and Safety Monitoring Board approves the usage of medium-dose ProTrans in the ongoing clinical trial.

Stem cell company NextCell Pharma AB ("NXTCL") announces today that the Data and Safety Monitoring Board for the clinical trial using ProTrans has given its approval for the principal investigator professor Per-Ola Carlsson and NextCell to proceed and treat 3 patients in the medium-dose cohort.

Läs mer

An update on NextCell Pharma and Nordic Tech House

NextCell Pharma’s (NXTCL) Board decided on 2018-03-13 to utilize its authorization to implement a targeted issue to Nordic Tech House. NextCell Pharma has identified Nordic Tech House as a strategic partner, which justifies deviation from shareholders’ preferential rights.

Läs mer

Nordic Tech House to invest in stem cell company NextCell Pharma

NextCell Pharma (NXTCL), traded at AktieTorget, announces that a collaboration with Nordic Tech House has been agreed upon where Nordic Tech House will invest in NXTCL and develop the digital presence of NXTCL and Cellaviva.

Läs mer

 

Kontakt Karolinska Institutet Science Park Hälsovägen 7, 141 57 Huddinge info@nextcellpharma.com +46 (0)8 735 55 95